Aptose Biosciences price target raised to $6 from $2 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Aptose Biosciences (APTO) to $6 from $2 and keeps a Buy rating on the shares. The firm is adjusting its estimate of the fully diluted share count based on the February 1:30 reverse split, removing second-line use of tuspetinib for acute myeloid leukemia from projections since the primary focus is on the triple first-line path and adjusting its projected launch year for first-line AML to 2030 in the U.S.